Cephalon offer for Arana now unconditional
This article was originally published in Scrip
Executive Summary
Cephalon's A$1.40 ($1.10) per share offer for the Australian antibody firm Arana Therapeutics has been declared final and unconditional, and is set to close on June 1st, unless extended. The move now means that Cephalon cannot increase the offer price, although it will rise to $1.45 per share if the US firm secures a holding of at least 90% during the offer period. It now holds a 53.4% stake. Arana shareholders will actually receive five cents a share less on settlement of the A$318 million acquisition, to adjust for a special five cent dividend already paid.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.